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Bimetra Biobank is the central high quality biorepository of University Hospital Ghent in collaboration 
with Ghent University (Belgium). Fully operational since 2015 in a new state-of-the-art biobank facil-
ity, Bimetra Biobank acts as a core facility for researchers and third parties looking for high-quality 
annotated clinical biospecimens. Bimetra Biobank stores about 120.000 clinical samples, both historical 
collections and prospective collections (disease-based collections, population-based collections and basic 
research collections) within well-defined and ethically approved research projects. Through a clear govern-
ance structure compliant with applicable laws, collections are operationally managed by Bimetra biobank 
personnel and samples releases are coordinated through collection specific coordinators and advisory 
boards. Biobank collections are open for collaborations to the international scientific community.
Keywords: hospital integrated biobank; clinical biobank; population biobank; high quality samples; service 
provider
Funding statement: The Bimetra Biobank facility was established with a one-off FFEU infrastructure fund 
(Flemish Government) and matching funds from Ghent University Hospital. The facility is operationally 
managed through a fee-for-service model complemented with an annual fee tumour biobanking (National 
Cancer Plan Minister Onkelinx, action 27).
(1) Bioresource Overview
Project description
The Bimetra Biobank is the central high-quality biore-
pository of Bimetra, the Clinical Research Centre (CRC) 
[1]. Bimetra was established in 2010 as central point of 
contact (CPOC) for facilitation of translational biomedical 
research within Ghent University Hospital in collabora-
tion with Ghent University. The mission of Bimetra is to 
reinforce the translation from basic research discovery 
studies to validation studies and clinical trials by creating 
an effective ‘discovery-to-care continuum’ towards health-
care innovation. Being able to build upon resources is key 
in accelerating translation and strengthening the position 
of Academic Health Centres. To achieve this goal, Bimetra 
is organised in five specialized platforms to facilitate spe-
cific research aspects (Figure 1).
Bimetra Biobank is a central biorepository at Ghent 
University Hospital, facilitating all aspects related to 
high quality sample processing, storage and distribution. 
Bimetra biobank acts as a core facility for local research-
ers and third parties in need of high quality biobanking. 
Local strategic prospective collections, important histori-
cal collections and interuniversity focus collections are 
operationally managed within the biobank. The collec-
tions in the Bimetra Biobank are diverse, ranging from 
disease-based clinical to population-based cohort collec-
tions, besides a cell line catalogue. A detailed overview of 
collections hosted at Bimetra Biobank can be found below 
under bioresource type.
The day-to-day operational management of Bimetra 
Biobank is performed by the biobank manager under 
supervision of the Head of Department of Bimetra. 
Sample processing, storage and associated data man-
agement is performed by the lab technicians. For each 
particular primary collection a coordinator (MD) is 
appointed, responsible for interactions with donors (ICF, 
sample prelevation, incidental findings, secondary use). 
For general/central collaborative collections, the coordi-
nator confers with an advisory committee of specialists 
regarding sample requests. E.g. for the tumour biobank 
collection, the tumour biobank coordinator confers 
with the multidisciplinary cancer-specific oncological 
advisory committee. The biobank manager facilitates 
sample requests handling in interaction with collection 
coordinators to ascertain approval for sample release. A 
general hospital biobank coordinator was appointed to 
oversee compliance with all applicable laws, policies and 
regulations.
An overview of the governance structure of Bimetra 
Biobank is described in Figure 2.
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Bimetra Biobank is part of the Flemish Biobank Network 
(Centre for Medical Innovation (CMI)), within the Belgian 
node BBMRI.be of the European Biobank Network BBMRI-
ERIC. The Flemish Biobank Network was officially founded 
in December 2009 through a collaborative effort between 
the Flemish Government, the Flemish Ministry of Economy 
and Scientific Affairs, the 5 universities and the 4 university 
hospitals and representatives of the Healthcare Industry. 
Bimetra Biobank together with each university hospital 
in this Network was able to set up a central high quality 
repository facility by 2015 through a one-off governmental 
funding (8 M EUR for all collaborating centres in total and 
matching funds from the participating institutions). The ini-
tiation of the Flemish Biobank Network and available fund-
ing led to jointly set up local biobank infrastructures within 
a harmonized quality framework, according to ethical and 
legal requirements, with common access procedures and an 
integrated interuniversity catalogue [2] of available samples. 
A uniform quality management system was implemented 
within this Network according to the International Society 
for Biological and Environmental Repositories (ISBER) Best 
Practices for Repositories Guidelines [3] and Organisation for 
Economic Co-operation and Development (OECD) guide-
lines for biorepositories [4] and is adapted for storage of 
Figure 1: Bimetra, Clinical Research Center Ghent.
Figure 2: Bimetra Biobank governance structure.
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different sample types in controlled and temperature mon-
itored Ultra Low Temperature (ULT) devices and isother-
mal freezers. Besides cryogenic storage capacity, Bimetra 
Biobank has established a laboratory for sample process-
ing (e.g. serum separation, buffy coat preparation, Quality 
Control (QC), Formalin-Fixed Paraffin Embedded (FFPE) 
slide and cryosection preparation, isolation of nucleic acids) 
which follows Good Laboratory Practices (GLP). The labora-
tory is located next to the storage facility, in order to mini-
mize critical transportation time of samples. All samples are 
registered in the biobank management system, SLims (from 
Genohm) [5] with an associated minimal dataset, includ-
ing International Statistical Classification of Diseases and 
Related Health Problems codes (ICD-10) and International 
Classification of Diseases for Oncology (ICD-O3) codes, 
both established by the World Health Organization (WHO). 
This is supplemented with the sample pre-analytical data 
to automatically generate the Standard PREanalytical code 
(SPREC) [6]. The flexibility of our biobank management 
system with integrated Electronic Lab Notebook (ELN) sys-
tem allows for easy automated collection of the parameters 
needed for the SPREC coding linked with information from 
various other databases. Throughout all collections minimal 
datasets are used, often linked to larger collection specific 
datasets making the datasets very valuable. In addition, the 
quality management system is provided with a document 
control system for Standard Operating Procedures (SOPs). 
Bimetra Biobank is partner of Biobanking and Biomolecular 
Resources Research Infrastructure (BBMRI.be), and there-
fore the collections of the Bimetra Biobank are accessible 
through the BBMRI.EU sample locator.
Classification (1)
Human.
Species
Human (Homo sapiens).
Classification (2)
Biological samples and associated clinical data.
Context
Spatial coverage
Bimetra Biobank is located in Ghent, Belgium.
Latitude: 51° 14′ 31.242″
Longitude: 3° 43′ 25.8024″
Temporal coverage
Retrospective collections since 2001.
Prospective collections gradually being built.
Temporal coverage for accessibility
Prospective collections are ongoing. No foreseen date of 
closure.
(2) Methods
Steps
The Bimetra Biobank has implemented a quality manage-
ment system, based on the harmonized quality guidelines 
for biobanks from the Flemish Biobank Initiative, devel-
oped in 2010 [7]. In the absence of a specific international 
quality standard for biobanking, the Flemish Biobank 
Network (former CMI, Centre For Medical Innovation) 
set out to make a set of quality standards, based on ISO 
9001:2008, ISBER Best Practices for Repositories [3] 
(version 2, 2008), the OECD Best Practice Guidelines 
for Biological Resource Centres (2007) [4], the WHO 
International Agency for Research on Cancer (IARC) 
Common minimum technical standards and protocols for 
biological resource centres dedicated to cancer research 
(2007) and the French standard NF S 96–900. Each CRC 
biobank of the Flemish Biobank Network implemented 
these quality standards and was positively peer review 
audited by the end of 2014.
Since 2012, Bimetra Biobank has implemented a pro-
fessional software system (IProva, Infoland) for document 
management (iDOCs) and registration of corrective and 
preventive actions (CAPA registration, IML) as a sound basis 
for the Quality Management System (QMS). Through the 
use of iDOCs, all documents pertaining to the QMS are 
kept in an electronic and web-based system, localized on 
a central server and through integrated user management, 
it is guaranteed that all authorised employees have access 
to the latest up-to-date documents. This system is used for 
development, management, controlled access, archiving 
and training of staff of all biobank related processes. This 
ranges from administrative processes, such as purchasing 
of consumables, facility access and training procedures, to 
operational processes, such as processing of samples, reg-
istration and follow-up of non-conformities and transport 
procedures. Furthermore, all performed procedures and 
flows are translated in specific SOPs, assuring high quality 
sample processing and storage. Additionally, every process 
step including specific processing information, storage con-
ditions and details, are recorded in the ELN of the database 
management system of the biobank, SLims. Samples pro-
cessed specifically at the Bimetra Biobank have real-time 
input of the data in the ELN module. By customisation and 
further development in SLims of a custom database flow, 
an overall integrated data collection flow is achieved, allow-
ing to generate automatically SPREC codes. Due to practical 
considerations regarding the sample quality, some sam-
ples are processed at other locations, and input of the data 
regarding processing is then captured through file transfer 
in order to generate the correct SPREC codes.
Sample processing follows general standard guidelines 
and procedures as shown in Table 1. However, within the 
setting of specific large-scale clinical trials, samples can be 
collected and processed with specific adapted procedures 
that are optimised for downstream analysis. The specifica-
tions of the adapted procedures are also registered in the 
ELN to keep a full traceability of the procedures followed. 
Access to biospecimens is possible in collaboration with 
the responsible researchers for well-defined purposes. 
Requests for storage and access should be forwarded to 
the Biobank Manager.
Stabilization/preservation
Samples can be delivered at the Bimetra Biobank in differ-
ent collection recipients, as indicated in Table 1. After sam-
ple processing, samples are stored in standard barcoded 
cryovials of 1.8 ml, 4 ml or 5 ml, aluminium cryocups of 3 
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to 5 ml, straws, stabilizer tubes (Paxgene tubes) or biobank-
ing tubes of 300 or 600 µl. The type of storage is dependent 
on the specific needs of the research project and requests 
from the researchers.
Type of long-term preservation
Frozen samples: in access-controlled and temperature-
monitored facility with locked –80°C freezers and isother-
mal freezers (LN2).
FFPE tissue samples: in access controlled and tempera-
ture-monitored storage cabinets.
Storage temperature
Isothermal freezers (–170°C to –190°C), –80°C, –35°C, 
–20°C, 4°C, room temperature (18°C–25°C).
Shipping temperature from patient/source to 
preservation or research use
0–4°C (on ice); room temperature (18–25°C).
Shipping temperature from storage to research use
–170°C to –190°C (liquid nitrogen), –80°C (on dry ice); 0 
–4°C (on ice); room temperature (18–25°C).
Quality assurance measures
Samples are processed according to harmonized pro-
cedures (SOPs), by trained staff. All process steps are 
recorded into the ELN of the sample- and data manage-
ment system, automatically generating the appropriate 
SPREC Code. The SPREC codes are a general indicator of 
the sample quality and the appropriateness of a sample to 
be included in specific types of analysis.
Yearly, a quality check of general tissue and liquid sam-
ples is performed. Specific care is taken into account for 
selection of the samples to be sacrificed for the quality 
control procedure, so that unique and rare samples are 
never accidentally selected.
Principal measures for ensuring the quality of samp 
les:
Table 1: Generic processing protocol data.
Type sample 
type
primary collection 
tube
Processing Freezing Aliquots Storage 
(main 
storage)
liquid sample serum serum separation tube 
with clot activator
1500 g at RT, 10 min slow rate freezing, 
ULT
3 to 6 –80°C
liquid sample plasma Potassium EDTA tube 815 g, 4°C, 10 min and 
2500 g, 4°C, 10 min
slow rate freezing, 
ULT
3 to 6 –80°C
liquid sample plasma low 
platelet
Potassium EDTA tube 3200 g at RT, 12 min 
and 2000 g, 4°C, 10 
min
slow rate freezing, 
ULT
3 to 6 –80°C
liquid sample plasma and 
RBC rest
Potassium EDTA tube 815 g, 4°C, 10 min and 
2500 g, 4°C, 10 min
slow rate freezing, 
ULT
3 to 6 –80°C
liquid sample buffy coat, 
viable PBMC
Potassium EDTA tube buffy coat separation 
with Lymphoprep
controlled rate 
freezing, ULT
up to 20 isothermal 
freezer
liquid sample cell lines NA NA controlled rate 
freezing, device
1 to 10 isothermal 
freezer
liquid sample urine 30 ml PP tube aliquoting slow rate freezing, 
ULT
1 –80°C
liquid sample semen straws aliquoting controlled rate 
freezing, device
multiple isothermal 
freezer
liquid sample reproduc-
tive material
cryovials and straws aliquoting controlled rate 
freezing, device
multiple isothermal 
freezer
solid sample stool 30 ml PP tube and 1.5 
ml PP tube
weighing and 
aliquoting
slow rate freezing, 
ULT
1 to 10 –80°C
solid sample frozen tis-
sue, tumor
NA macroscopical dissec-
tion and freezing
snapfreezing 
isopenthane
1 to 5 –80°C
solid sample frozen tis-
sue, normal
NA macroscopical dissec-
tion and freezing
snapfreezing 
isopenthane
1 to 5 –80°C
solid sample frozen tis-
sue, other
NA macroscopical dissec-
tion and freezing
snapfreezing 
isopenthane
1 to 5 –80°C
solid sample FFPE tissue NA formalin fixation and 
parafin embedding
NA 1 to 5 RT
solid sample reproduc-
tive material
cryovials macroscopical dissec-
tion and freezing
controlled rate 
freezing, device
multiple isothermal 
freezer
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•	 Govern the suitability of reagents and laboratory 
materials.
•	 Ensure an immediate intervention in case of an elec-
trical blackout to safeguard samples with proper 
alarm systems for all freezers.
•	 Have a risk-management storage system for each sam-
ple in separate freezers.
•	 Maintain the database up-to-date.
Checks that are performed:
•	 DNA extraction, quantification and integrity check 
with DNA Integrity Number (DIN) assessment
•	 RNA extraction, quantification and integrity check 
with RNA Integrity Number (RIN) assessment
•	 Buffy coats: viability checks
When samples are requested, dependent on the type of 
sample, additional checks are performed.
•	 all samples:
 ◦ location check
 ◦ check of required volume and amount of aliquots
 ◦ check of the SPREC code and appropriateness with 
regard to the specific analysis
•	 tissue samples:
 ◦ preparation of a cryosection with Hematoxylin and 
Eosin (H&E) staining
 ◦ evaluation performed by a pathologist
In 2016, the Bimetra Biobank participated in the Integrated 
Biobank of Luxembourg (IBBL) proficiency testing (ISBER 
endorsed) for DNA extraction from tissues, DNA quantifi-
cation, RNA extraction from tissues, RNA quantification 
and buffy coat preparation. The Bimetra Biobank per-
formed very satisfactory in all categories.
Source of associated data
As mentioned before, the Bimetra Biobank has imple-
mented several minimal datasets:
•	 for tumour related material: tumour biobank minimal 
dataset with ICD-O3 coding and TNM Classification of 
Malignant Tumours (TNM) coding
•	 for other collections: Flemish Biobank Network mini-
mal dataset with ICD-10 coding for diseases
Both minimal datasets also include all parameters needed 
to generate the SPREC coding. All this data is recorded 
and kept in the sample- and data management system, 
SLims. The system is customised according to the Bimetra 
Biobank specific needs. Furthermore, the minimal data-
set can be extended to project specific datasets. Patient 
and disease related data is collected through automatic 
data retrieval from several linked databases, such as the 
electronic patient health records and pathology records. 
These database connections are strictly project specific 
and established after all legal and ethical approvals are 
obtained. The automatic data retrieval minimizes the 
risks in mistakes or misidentifications. This data can be 
completed with data from questionnaires and laboratory 
analysis, inputted manually or through coupling with 
electronic Case Report Form (eCRF) modules.
To improve accessibility and visibility of the samples 
and data sharing for translational clinical research, the 
Flemish Biobank Network has recently set up a cata-
logue of biobank samples [2]. The catalogue maps dif-
ferent data sets and subsets from autonomous database 
systems enabling aggregated query results and thresh-
old induced notifications for participating researchers 
(Figure 3). At each Partner Biobank within the Network, 
harmonized datasets are uploaded to a local Opal data-
base. Aggregated results of a subset of the variables is 
made available to the central catalogue, Mica (referred 
to as the central backbone in figure), which is query 
able in real-time through the online catalogue. A veri-
fied email address suffices for querying the Minimal 
Data Set of 12 variables. Query terms can be added 
using real-time filtering of ontologies (ICD-10, ICD-O-
3) or aided by statistics of the variable. No individual-
level data passes through Mica (the central backbone), 
yet researchers can assess the suitability of a dataset 
for their needs. The results are shown as grouped data 
with a total result of matching samples to query data. 
The sample can be requested through sample access 
flows, specific to each partner of the Flemish Biobank 
Network.
Ethics Statement
All collections managed within the Bimetra Biobank 
have been established in the context of a predefined 
research project for which an Institutional Ethical 
Review Board approval was obtained. All projects com-
ply with the Declaration of Helsinki (Ethical Principles 
for Medical Research Involving Human Subjects) and the 
Good Clinical Practice (GCP) regulation and Data protec-
tion regulations.
Primary use of samples is accepted only within the 
predefined research goals, secondary use is subject to a 
revised Ethical Board approval and in addition the donors 
need to be recontacted to reconsent to the secondary pur-
poses. All data related to the donor collected in the data-
base system, are pseudonymised. The database system, 
Slims, implies a coding strategy which is compliant with 
current privacy regulations, and will be updated for imple-
mentation of GDPR.
Constraints
N/A
(3) Bioresource description
Object name
Bimetra Biobank
Bioresource name
Bimetra Biobank UZ Gent
Bioresource location
Bimetra Biobank
UZ Ghent
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De Pintelaan 185 -1DWR
9000 Ghent
Belgium
The Bimetra Biobank is located at Ghent University 
Hospital. The central biobank facility is located at DWR, -1 
(basement). There are multiple sample collection points at 
the University Hospital, such as the Pathology Department 
for tissue samples and the central clinical lab for blood, 
serum and plasma samples.
Bioresource contact
bimetra.biobank@uzgent.be
Bioresource URL
www.bimetra.be/biobank
Identifier used
BE_71067049; Bimetra Biobank @ UZ Gent, BBMRI-ERIC
Bioresource type
The Bimetra Biobank is a central hospital integrated 
biobank, comprising of a number of disease-oriented 
biobanks, population-based biobanks and basic research 
collections.
•	 Disease-oriented biobanks:
 ◦ Hepatotropic pathogens: HCV and HBC
 ◦ Inflammatory Bowel Diseases: Colitis Ulcerosa, 
Crohn’s disease
 ◦ Rheumatoid arthritis
 ◦ Chronic Obstructive Pulmonary Disease (COPD)
 ◦ Chronic Renal failure
 ◦ Neurodegenerative diseases: Multiple Sclerosis
 ◦ Cancer related collections
•	 Cancer tissue bank (solid tumours): prostate can-
cer, breast cancer, urothelial cancer, cervix can-
cer, lung cancer…
•	 Cancer serum collection
•	 Pediatric hemato-oncology biobank
•	 Population based biobanks:
 ◦ Asklepios collection (cardiovascular risk factors and 
aging (longitudinal cohort))
 ◦ Twin registry (East-Flemish Twin register)
 ◦ Hepatotropic pathogens: population serum collection
•	 Basic research collections
 ◦ Human embryonic stem cells and iPS cells for stem 
cell research
 ◦ Reproductive health collections
 ◦ Cancer cell line collections (human): primary and 
immortalized
Type of sampling
Operational management of multiple type collections:
•	 population-based cohort collections with longitudi-
nal follow-up
•	 disease-based collections
•	 hospital-based clinical collections (residuary material 
after diagnosis)
•	 hospital-based clinical trial collections
•	 tumour biobank collections
Anatomical site
Several anatomical sites in the body are covered, depend-
ing on the focus of the collection.
Disease status of patients/source
Available.
Figure 3: Overview of the data-structure of the Flemish Biobank Backbone.
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Clinical characteristics of patients/source
As mentioned in the associated data, a minimal dataset is 
accessible for each sample in the Bimetra Biobank, with 
inclusion of ICD-10 or ICD-O3 and TNM Classification of 
Malignant Tumours codes (for tumour related samples). 
Project specific extended datasets with multiple clinical 
parameters and questionnaire information can be made 
available in the research collaboration, depending on the 
type of collection and the criteria followed for sample and 
data collection.
Vital state of patients/source
Alive at time of sampling.
Small collection of post-mortem samples.
Clinical diagnosis of patients/source
Available in dataset: ICD-10 or ICD-O3 classification.
Healthy collections and disease-based collections.
Pathology diagnosis
Available in dataset when applicable.
Control samples
Control samples are available in multiple specific collec-
tions. Most frozen residual tumour samples are stored 
with matching normal tissue. Several collections have 
healthy control samples available.
Biospecimen type
A different variety of samples is available, depending on 
the specific project and related research settings, such 
as serum, plasma, platelet low plasma, viable Peripheral 
Blood Mononuclear Cells (PBMCs), tissue, cells, DNA, RNA, 
cell lines, urine, stool...
Size of the bioresource
Bimetra Biobank is not a project, but is part of the CRC 
Bimetra and has no fixed expiry date. The size of each 
project collection within the Bimetra Biobank varies. In 
general, about 120.000 samples are currently present in 
the Bimetra Biobank, originating from different research 
projects and in collaboration with multiple research-
ers, comprising both prospective and historical collec-
tions. In Figures 4 and 5, an overview of the amount 
of stored samples and distribution of samples can be 
found.
Release date
Data and samples in the collections are available within 
the context of well-defined research collaborations in con-
sensus with all parties involved.
Access criteria
Samples and associated data from collections within the 
Bimetra Biobank can be applied for further biomedical 
research. A sample request can be launched through the 
Flemish Biobank Backbone [7], through the sample loca-
tor of BBMRI (national node BBMRI.be) or by filling in the 
sample request form on the Bimetra biobank website [9], 
using a set of minimal parameters. Every researcher world-
wide can send in a request to the Biobank.
Bimetra Biobank will facilitate downstream processes 
regarding the sample request (such as contacting the 
coordinator of the collection and sample flow release, 
assistance and (p)review of an IRB approval to ensure that 
the planned methods on the requested samples are ethi-
cally sound, research agreement negotiations, QC control 
of the requested material and sample transport). In addi-
tion, Bimetra Biobank has implemented and executed 
SOPs for retrieval of samples and data within its quality 
management system. The Bimetra Biobank will act as a 
trusted third party collaboration, ensuring patient/donor 
coding/anonymity.
The costs will vary related to the type and amount of 
samples that are shipped and the specific data that is 
requested, as is set out in the research agreement with 
integrated Material Transfer Agreement (MTA)/Data 
Transfer Agreement (DTA).
(4) Reuse potential
Samples and data in the Bimetra Biobank collections can 
be used in different scientific projects. A sample request 
can be launched by filling in the sample request form on 
Figure 4: Bimetra Biobank: overview of sample storage 
and sample exchange (up to September 2017).
Figure 5: Bimetra Biobank: overview of sample storage 
and sample exchange (up to September 2017).
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the Bimetra biobank website [9]. Additional clinical data 
related to Biobank samples can be traced through the 
electronic health record systems via the treating physician 
or the medical ‘controller’ (as following Belgian legisla-
tion concerning the requirements for collection, storage 
and use of human bodily material for research purposes), 
and aligned with the IRB approval and the provisions in 
the research collaboration agreements on the sample and 
data use.
In sample distribution, Bimetra Biobank acts as a 
trusted third party, ensuring donor anonymity by coding 
of the samples. The applicant must follow the agreements 
made in the MTA/DTA with the primary researchers of the 
collection and acknowledge the Bimetra Biobank, accord-
ing to the COBRA guidelines [10] for standardised biore-
pository citations. The actual citation for each collection, 
with unique reference number, is specified in the MTA 
agreement.
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